We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Next-Generation DNA Sequencer Platform Is Small and Affordable

By LabMedica International staff writers
Posted on 02 Jun 2010
A benchtop next-generation DNA sequencing platform is ideally suited for labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial-genome sequencing, metagenomic analysis, as well as novel pathogen detection.

The GS Junior System includes a suite of high-performance data analysis software, offering a solution for scientists who are less experienced in DNA sequencing technologies and bioinformatics. More...
The software package includes tools for de novo genome and transcriptome assembly and mapping, as well as amplicon variant analysis for the identification of rare variants in targeted sequencing studies.

Roche (Basel, Switzerland) announced the global launch of the GS Junior System, the company's new DNA sequencing platform. Developed by 454 Life Sciences (Branford, CT, USA), a Roche company, the system provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency, and price competitiveness, small and medium sized laboratories worldwide will have access to Roche's state-of-the-art sequencing capabilities at an affordable price.

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double-digit growth expected for the next several years.

Roche's Genome Sequencer FLX System has enabled hundreds of scientific discoveries, including the identification of novel pathogenic viruses, the analysis of ancient DNA from Neanderthal man and the wooly mammoth, and the characterization of microbial communities in the human gut.

"Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turnaround time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications,” said Daniel O'Day, COO of Roche Diagnostics (Indianapolis, IN, USA).

Roche is a leader in research-focused healthcare with combined strengths in diagnostics and pharmaceuticals. It is also a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche
454 Life Sciences
Roche Diagnostics



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.